{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-015224","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2025-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.912752+00:00","generated_at":"2026-05-26T10:26:58.864534+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"confidence":"high","headline":"Marker Therapeutics grants 50,000 CEO options and 30,000 options each to three non-employee directors","bullets":["CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.","Non-employee directors David Eansor, Katherine Knobil, and Steven Elms each receive 30,000 options with same vesting.","Awards approved by Compensation Committee and Board on February 12, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-015224","json":"https://secwatch.observer/filing/0001104659-25-015224.json","markdown":"https://secwatch.observer/filing/0001104659-25-015224.md","text":"https://secwatch.observer/filing/0001104659-25-015224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925015224/0001104659-25-015224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465925015224/tm257101d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T10:26:58.864534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}